Valuation: Incyte Corporation

Market Cap 23.45B 118B 20.94B 19.35B 17.53B 32.8B 2,226B 33.35B 233B 92.18B 1,167B 88.02B 86.15B 3,678B P/E 2026 *
64.5x
P/E 2027 * 16.3x
Enterprise Value 19.19B 96.65B 17.13B 15.83B 14.34B 26.83B 1,821B 27.28B 190B 75.4B 954B 72B 70.47B 3,008B EV / Sales 2026 *
3.23x
EV / Sales 2027 * 2.81x
Free-Float
98.15%
Yield 2026 *
-
Yield 2027 * -
1 day+2.54%
1 week+2.54%
Current month-11.49%
1 month-11.49%
3 months-2.28%
6 months+22.07%
Current year+4.03%
1 week 288.27
Extreme 288.27
288.55
1 month 280
Extreme 280
310.93
Current year 232.56
Extreme 232.56
328.68
1 year 232.56
Extreme 232.56
328.68
3 years 135.9
Extreme 135.9
328.68
5 years 135.9
Extreme 135.9
328.68
10 years 135.9
Extreme 135.9
328.68
Manager TitleAgeSince
Chief Executive Officer 58 26/06/2025
Director of Finance/CFO 57 04/05/2026
President 62 05/06/2023
Director TitleAgeSince
Chairman 59 26/06/2025
Director/Board Member 72 20/01/2015
Director/Board Member 64 20/01/2015
Change 5-day change 1-year change 3-year change Capi.($)
+2.54%+2.54% - - 23.45B
+0.24%+2.93%+54.48%+124.72% 1,135B
+0.81%+4.88%+39.87%+78.63% 635B
+0.34%+1.36%+25.65%+97.33% 505B
+1.45%+4.21%+48.13%+66.95% 378B
-2.16%-1.29%+61.11%+34.32% 358B
-0.52%+2.35%+23.23%+49.39% 295B
-0.02%+3.37%+2.17%+23.34% 266B
+0.34%+3.90%+51.64%+63.70% 237B
+1.54%+3.53%+31.54%+101.87% 193B
Average +0.40%+1.60%+37.54%+71.14% 444.85B
Weighted average by Cap. +0.19%+1.63%+41.47%+83.40%

Financials

2026 *2027 *
Net sales 5.94B 29.91B 5.3B 4.9B 4.44B 8.3B 564B 8.44B 58.94B 23.33B 295B 22.28B 21.81B 931B 6.24B 31.44B 5.57B 5.15B 4.67B 8.73B 592B 8.87B 61.95B 24.53B 310B 23.42B 22.92B 979B
Net income 377M 1.9B 336M 311M 282M 527M 35.77B 536M 3.74B 1.48B 18.74B 1.41B 1.38B 59.08B 1.48B 7.47B 1.32B 1.22B 1.11B 2.07B 141B 2.11B 14.72B 5.83B 73.75B 5.56B 5.45B 233B
Net Debt -4.27B -21.5B -3.81B -3.52B -3.19B -5.97B -405B -6.07B -42.38B -16.78B -212B -16.02B -15.68B -669B -5.95B -29.95B -5.31B -4.91B -4.45B -8.32B -564B -8.45B -59.03B -23.37B -296B -22.32B -21.84B -932B
Projected Income Statement - Annual - Incyte Corporation
Logo Incyte Corporation
Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows: - product sales (84.7%); - royalties (12.4%); - income from research and cooperation agreements (2.9%).
Employees
2,844
Date Price Change Volume
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - Incyte Corporation
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
115.71USD
Average target price
129.54USD
Spread / Average Target
+11.95%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Incyte Corporation